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EpidemiologyIntroduction: Two types of vaccines are currently licensed for use against pertussis: whole-cell (wP) and
acellular pertussis (aP). There is evidence that wP confers more durable immunity than aP, however wP
has been more frequently associated with adverse events following immunisation (AEFI). A comparison
of the frequency of AEFI with the first doses of wP and aP has not yet been clearly documented. This must
be done in light of recent considerations to move towards a wP prime-aP boost vaccination strategy in
low and middle-income countries.
Objectives: To compare the frequency of AEFI associated with the first dose of the wP and aP vaccines. We
also compared the frequency of AEFI associated with subsequent doses of wP.
Methods: This systematic review was carried out in strict accordance with the published protocol.
Results: High heterogeneity amongst included one-armed studies did not allow for pooling of prevalence
estimates. The prevalence estimates of AEFI at first vaccine dose of wP ranged from 0 to 75%, while the
prevalence estimates of AEFI at first vaccine dose of aP ranges from 0 to 39%. The prevalence estimates of
adverse events following second and third vaccine dose of wP ranged from 0 to 71% and 0 to 61%, respec-
tively.
Risk ratios among two-armed studies showed an increased risk of adverse events with first dose of wP
compared to aP [local reaction RR 2.73 (2.33, 3.21), injection site pain RR 4.15 (3.24, 5.31), injection site
swelling RR 4.38 (2.70, 7.12), fever over 38 C RR 9.21 (5.39, 15.76), drowsiness RR 1.34 (1.18, 1.52) and
vomiting RR 1.28 (0.91, 1.79)].
Conclusion: Our results confirm that, when comparing the first dose, wP is more reacotgenic than aP. The
proposed wP prime followed by aP boost pertussis vaccine strategy should be approached with caution.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pertussis, or ‘‘whooping cough”, is a highly contagious respiratory
illness. It is caused by the gram-negative bacterium Bordetella per-
tussis (B. pertussis), an exclusively human pathogen [1]. Bordetella
pertussis is spread from person to person through respiratory dro-
plets dispersed by coughing and sneezing [2]. Currently, there are
two types of pertussis vaccines licensed for use: whole cell pertus-
sis (wP) and acellular pertussis (aP). Unlike aP, wP vaccines havebeen frequently associated with adverse events following immuni-
sation (AEFI) [3]. Public concerns due to reports of AEFI associated
with wP vaccines led to manymiddle and high-income countries to
use of aP vaccines beginning in the 1980s [4].
Immunisation with either wP or aP vaccines as well as natural
infection do not confer lifelong immunity against B. pertussis.
Consequently, cyclical peaks in the incidence of the disease have
historically occurred every 3 to 5 years [5,6]. In recent years, the
peaks have begun to occur more frequently, indicating a possible
rise in pertussis incidence [6]. In spite of estimated global pertussis
vaccination coverage being as high as 82% for 3 doses, the disease
continues to occur worldwide [4,7]. Interestingly, a number of
countries (e.g. Australia, Portugal, the UK and the USA) that have
switched from the using wP to aP have reported pertussis resur-
gence several years following the switch [4]. Although there are
6008 J. Patterson et al. / Vaccine 36 (2018) 6007–6016conflicting reports regarding which of the two pertussis vaccines
has better efficacy, aP vaccines are reported to confer shorter dura-
tion of protection in comparison to wP vaccines [8].
The World Health Organization’s (WHO) 2015 pertussis position
paper recommends that countries currently using wP for primary
schedules (doses 1–3) should continue to do so [4]. The WHO sug-
gests that switching from use of wP to aP should only be consid-
ered if additional boosters and/or maternal immunisation can be
sustained at a national level, which could impose financial implica-
tions on countries [4]. A combination vaccination strategy has been
suggested, which would include ‘‘priming” infants and children
using wP at first dose and thereafter completing the primary
schedule with aP [9–11]. Immunological and modelling evidence
suggests that, if implemented, this combined approach could
induce better protective immunity than the current exclusive aP
approaches. Additionally, it is hoped that the combined vaccina-
tion strategy would result in fewer AEFI than currently experi-
enced with the exclusive use of wP [12].
An important factor in considering this combined vaccination
strategy is the safety of wP vaccines at first dose. It is, therefore,
necessary to estimate the prevalence of AEFI associated with the
first dose of wP and to assess how these estimates compare in fre-
quency and severity to those associated with the first dose of aP
vaccines. To the best of our knowledge, there is currently no pub-
lished and systematised comparison of AEFI at first dose of pertus-
sis vaccines.
1.1. Objectives of review
This systematic review identified all qualifying literature that
involved children six years and younger who received a vaccine
dose against pertussis in a primary vaccination schedule (doses
1–3) (See Methods).
Primary objectives:
 To describe the frequencies of AEFI associated with first dose of
wP vaccines
 To describe the frequencies of AEFI associated with second and
third dose of wP vaccines
 To describe the frequencies of AEFI associated with first dose of
aP vaccinesTable 1
Criteria for study inclusion.
Characteristic Inclusion criteria
Type of study Cohort studies, case-control studies,
vaccine surveillance studies, or rand
Participants Including infants and children 6 yea
pertussis in a primary vaccination sc
Case definition Pertussis vaccine-related adverse ev
 Generalised local reactions (ex. I
 Injection site swelling
 Injection site tenderness
 Decreased injected limb movem








Outcome measures Primary outcomes:
 Prevalence of adverse events fol
with first vaccine dose of wP
 Prevalence of adverse events fol
with first vaccine dose of aPSeco
 Prevalence of adverse events fol
and third vaccine doses of wP
Abbreviations: wP = whole-cell pertussis, aP = acellular pertussis.Secondary objectives:
 To compare the frequencies of AEFI associated with first dose of
wP and aP vaccines
 To compare the frequencies of AEFI associated with first and
second/third dose of wP vaccines
2. Methods
Systematic review methods used in conducting this study have
been published elsewhere and the study protocol registered on
PROSPERO (registration number CRD42016035809) [13].2.1. Eligibility criteria
Literature inclusion was restricted to published studies that evalu-
ated pertussis vaccine-related AEFI in participants 6 years old or
younger within 72-hours of vaccine administration. Criteria for
including studies are outlined in Table 1.2.2. Search strategy
The following databases were searched for the relevant literature:
Africa-Wide, CINAHL, ClinicalKey, CENTRAL, MEDLINE via PubMed,
PDQ-Evidence, Scopus, Web of Science Biological Abstracts, Web of
Science Core Collection and WHOLIS. A combination of the follow-
ing search terms (including the use of MeSH) was used: adverse
event, pertussis vaccine, whole cell pertussis vaccine, and acellular
pertussis vaccine. The search strategy, as applied to PubMed, is
outlined in Table 2. The initial search was run in May 2016 and
updated in September 2017. The updated search did not yield
any new literature to add to the review.2.3. Screening and study selection
Two authors (JP and RM) screened the search outputs using titles
and abstracts first. Thereafter, the two authors independently went
through the full text of all potentially eligible studies to assess if
they met the inclusion criteria. Discrepancies in the list of eligiblecross-sectional studies, post-marketing
omised controlled trials published in a peer reviewed journal
rs or younger vaccinated against
hedule












































Fig. 1. Flow diagram for
Table 2
Search strategy for PubMed.
Query Search term
#1 adverse event OR adverse effect OR adverse events following
immunisation OR AEFI
#2 ‘‘Pertussis Vaccine” (MeSH) OR pertussis vaccine OR whooping cough
vaccine
#3 whole cell OR wP OR DTP OR DwPT
#4 ‘‘Vaccines, Acellular/adverse effects” (MeSH) OR acellular OR aP OR
DaPT
#5 #1 AND #2 AND (#3 OR #4)
Note: Human participants and age of participants are included in search filter.
J. Patterson et al. / Vaccine 36 (2018) 6007–6016 6009studies between the two authors were resolved through discussion
and consensus with the assistance of the other authors.
2.4. Data extraction and management
Data was extracted from the included studies on a pre-designed
data extraction form using TapForms software [14]. Data were then
extracted and entered into STATA version 14 for analysis [15].
2.5. Risk of bias and quality assessment
Each article included was assessed for risk of bias and quality.
Observational studies were assessed using the appropriate CASPh
Duplicates removed
(n=1 260)
Records excluded in screening
(n=1 191), with reasons
Not related to pertussis AND vaccine
related adverse events
(n=1 191)
Full-text arcles excluded (n=462),
with reasons
AEFI not presented by dose number or
type of vaccine (n=146)
Study design did not fit protocol (n=173)
Populaon denominator not given in
study (n=20)
AEFI case definion not matched by
protocol (n=60)
AEFI reporng meframe was > 72 hrs
(n=43)
Full text not found (n=18)
Arcle withdrawn from publicaon (n=1)
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[16,17]. All risk of bias judgements were made by the first author
and checked by BK.2.6. Data synthesis and analyses
The Preferred Reporting Items for Systematic reviews and Meta-
analyses (PRISMA) checklist was used in reporting the findings
of this review [18]. As the data were collected from a series of
independently performed studies which inherently included sub-
jects from different populations, a random effects model was fit-
ted to the data. The prevalence of AEFI were compared by vaccine
type (wP and aP) in the data analysis. Where heterogeneity was
found to be low in meta-analyses (I2 < 50), pooled prevalence
estimates were reported with 95% confidence intervals for each
respective outcome. Where heterogeneity was found to be high
in meta-analyses (I2 > 50), narrative reporting was used to
describe the mean and ranges of prevalence for each respectiveTable 3
Characteristics of studies included in the review.
Author, Year [citation] Study Design Country In
Anderson, 1988 [19] RCT USA H
Auerbach, 1992 [20] RCT USA H
Barkin, 1984 [21] RCT USA H
Bell, 1999 [22] RCT UK H
Bernstein, 2011 [23] RCT USA H
Beyazova, 2013 [24] RCT Turkey U
Black, 1993 [25] RCT USA H
Carlsson, 1998 [26] RCT Sweden H
Cody, 1981 [27] RCT USA H
Dagan, 1994 [28] RCT Israel H
Decker, 1995 [29] RCT USA H
Deloria, 1995 [30]# RCT USA H
Ducusin, 2000 [31] Post-marketing surveillance Philippines L
Fateh, 2014 [32] RCT Iran U
Feery, 1982 [33] Cohort Australia H
Greenberg, 2000 [34] RCT USA H
Halperin, 1996 [35] RCT Canada H
Hoppenbrouwers, 1999 [36] RCT Turkey U
Huang, 2010 [37] Cohort USA H
Hussey, 2002 [38] Cohort South Africa U
Kallings, 1988 [39] RCT Sweden H
Kayhty, 2005 [40] Cohort Sweden H
Korkmaz, 2014 [41] Cohort Turkey U
Langue, 1999 [42] RCT France H
Lee, 1999 [43] RCT China U
Liese, 2001 [44] Cohort Germany H
Long, 1990 [45] RCT USA H
Mallet, 2000 [46] RCT France H
Martins, 2007 [47] Cohort Brazil U
Miller, 1991 [48] RCT UK H
Miller, 1995 [49] RCT UK H
Monteiro, 2010 [50] Post-marketing surveillance Brazil U
Murphy, 1983 [51] RCT USA H
Nolan, 1997 [52] RCT Australia H
Paradiso, 1993 [53] RCT USA H
Pichichero, 1992 [54] RCT USA H
Pichichero, 1994 [55] RCT USA H
Pichichero, 2002 [56] Cohort Sweden H
Pollock, 1984 [57] RCT UK H
Prymula, 2008 [58] Cohort Czech Republic H
Schmitt, 1996 [59] RCT Germany H
Simondon, 1996 [60] RCT Senegal L
Trollfors, 1995 [61] RCT Sweden H
Usonis, 1996 [62] RCT Lithuania H
Vadheim, 1993 [63] RCT USA H
Waight, 1983 [64] Cohort UK H
Watemberg, 1991 [65] RCT Israel H
Abbreviations: wP = whole-cell pertussis, aP = acellular pertussis, RCT = randomized co
inclusion in comparative meta-analysis of two-armed studies.outcome. Due to insufficient data, none of the subgroup analyses
outlined in the study’s protocol were able to be carried out.
3. Results
In total 1 699 records were retrieved from the electronic database
searches, of which 508 were selected for full-text review. A further
462 records were excluded, leaving 47 studies that met the final
inclusion criteria (Fig. 1). The included studies were further split
into one-armed studies that reported AEFI associated with either
wP or aP vaccines (36 studies) or two-armed studies that com-
pared the occurrence of AEFI associated with wP and aP vaccines
in the same population (11 studies). The included studies were
published between 1981 and 2014 in low-middle (2 studies),
upper-middle (8 studies) and high (37 studies) income countries.
The included literature was made up of 2 post-marketing surveil-
lance studies, 10 cohort studies and 35 randomised controlled tri-
als (RCTs). The studies included a total of 450 757 individuals. The
characteristics of included studies are summarised in Table 3. Ofcome Level Vaccine (s) Sample size Reporting Method Time
igh wP and aP 39 Doctor/Nurse Consult 72
igh aP 160 Doctor/Nurse Consult 24
igh wP 54 Doctor/Nurse Consult 72
igh aP 251 Parental reporting card 72
igh aP 568 Parental interview 72
pper-middle wP and aP 778 Parental reporting card 72
igh wP 946 Parental interview 72
igh aP 235 Parental reporting card 72
igh wP 4964 Parental questionnaire 72
igh wP 73 Parental reporting card 72
igh wP and aP 2184 Parental reporting card 72
igh wP and aP 2127 Parental interview 48
ow-middle wP 1036 Parental questionnaire 72
pper-middle wP 235 Doctor/Nurse Consult 48
igh wP 3565 Parental interview 72
igh aP 405 Parental reporting card 72
igh wP and aP 208 Parental interview 48
pper-middle aP 258 Parental reporting card 72
igh aP 388,335 Surveillance system 72
pper-middle wP 129 Parental reporting card 72
igh aP 2847 Parental reporting card 24
igh aP 101 Parental reporting card 72
pper-middle wP and aP 1324 Parental reporting card 72
igh wP 213 Parental reporting card 72
pper-middle aP 67 Parental reporting card 48
igh aP 1779 Parental reporting card 72
igh wP 536 Parental reporting card 48
igh aP 848 Parental reporting card 72
pper-middle wP 9259 Parental interview 48
igh wP and aP 176 Doctor/Nurse Consult 24
igh wP and aP 177 Doctor/Nurse Consult 24
pper-middle wP 3178 Surveillance system 12
igh wP 206 Parental reporting card 24
igh wP 812 Parental reporting card 12
igh wP 188 Parental reporting card 72
igh wP and aP 290 Parental interview 48
igh wP and aP 80 Parental reporting card 72
igh wP and aP 110 Parental reporting card 48
igh wP 5408 Parental interview 12
igh aP 2479 Parental reporting card 72
igh aP 2455 Parental reporting card 24
ow-middle wP and aP 241 Doctor/Nurse Consult 72
igh wP 1724 Parental reporting card 48
igh wP 119 Parental interview 72
igh wP 1834 Parental reporting card 72
igh wP 144 Doctor/Nurse Consult 24
igh wP 56 Parental reporting card 72
ntrol trial, time = maximum adverse event reporting time, # insufficient data for
J. Patterson et al. / Vaccine 36 (2018) 6007–6016 6011the selected studies, although 12 investigated both wP and aP
interventions, one did not have sufficient data for inclusion in
the comparative meta-analysis.
3.1. Methodological quality
Bias assessment of included observational studies was categorised
by a score of low, moderate or high derived from CASP checklists
(Table 4). Risk of bias assessments of included randomised control
trials is displayed in Fig. 2.
3.1.1. Single-Armed studies
As heterogeneity was found to be high between all single-armed
studies assessing the prevalence of AEFI with both wP and aP vac-
cines, prevalence estimates for these studies were not pooled. Due
to a wide range of wP and aP vaccine brands utilized in the
included studies, prevalence of AEFI according to vaccine brand
could not be assessed.
3.1.1.1. Adverse events associated with first dose of whole-cell and
acellular pertussis. Fever over 38 C was the most commonly sur-
veyed AEFI following first dose of wP (18 studies), while
hypotonic- hyporesponsive episode (HHE) was the least commonly
surveyed (3 studies). The prevalence of any AEFI with first dose ofTable 4
Risk of bias assessment for observation studies.
Author, Year Risk of Bias CASP
Auerbach, 1992 Low
Barkin, 1984 Low






Cody, 1981 Moderate (a) co
Dagan, 1994 Low
Deloria, 1995 Moderate (a) co
trial




Gustafsson, 1996 Moderate (a) co
impor
Hoppenbrouwers, 1999 Moderate (a) co
Huang, 2010 Moderate (a) co
Hussey, 2002 Low





Long, 1990 Low (a) co
Mallet, 2000 Low
Martins, 2007 Moderate (a) co




Pollock, 1984 High (a) co
could
Prymula, 2008 Low
Schmitt, 1996 Moderate (a) co
apart
Trollfors, 1995 Low
Usonis, 1996 Moderate (a) co
Vadheim, 1993 Low
Vanura, 1994 Moderate (a) co
Waight, 1983 Low
Watember, 1991 LowwP ranged from 0 to 75%, with irritability reported as most
prevalent.
Fever over 38 C was the most commonly surveyed AEFI following
first dose of aP (14 studies). None of the studies using aP reported
on seizure or HHE occurrence. The prevalence of AEFI with first
dose of aP ranged from 0 to 39%, with irritability as most prevalent.
Fig. 3A represents a narrative forest plot comparison of mean
prevalence with ranges for AEFI at first dose of wP and aP vaccines.
Adverse events (except persistent crying) were more prevalent fol-
lowing first dose of wP as compared to first dose of aP. The mean
prevalence of persistent crying, however, was 11% for wP as com-
pared to 23% for first dose of aP. The frequency of AEFI showed
noticeably higher variability for wP estimates as compared to aP
estimates.
In the included studies, wP was administered as a dose of stan-
dalone DTwP or commonly as DTwP in a combination formulation
with polio, hepatitis B, and haemophilus influenzae type B.
Fig. 3B represents a narrative forest plot of the mean prevalence
with ranges for AEFI at first dose of wP administered as a stan-
dalone dose of DTwP or in DTwP combination formulation. Stan-
dalone and combined formulations showed an overlap in the
frequency of AEFI with the exception of drowsiness and vomiting.
Only three studies, however, were available in each arm to assesses
drowsiness, while two and three were available in each are toScore Description
udy was not blinded, (b) aside from the intervention, groups were not treated
ly, (c) could not tell if all patients at the beginning of trial were accounted for at
usion
uld not tell if groups were similar at start of trial
uld not tell if study was blinded, (b) could not tell if groups were similar at start of
uld not tell if confounding variables were taken into account in analysis
uld not tell if groups were similar at start of trial, (b) could not tell if all clinically
tant outcomes were considered
uld not tell if study was blinded
uld not tell if confounding variables were taken into account in analysis
uld not tell if all clinically important outcomes were considered
uld not tell if groups were similar at start of trial
uld not tell if confounding variables were taken into account in analysis
uld not tell if confounding variables were taken into account in analysis
uld not tell study was randomised, (b) could not tell if study was blinded, (c)
not tell if all patients at beginning of trial were accounted for at conclusion
uld not tell if study was blinded, b) could not tell if groups were treated equally
from intervention
uld not tell if groups were similar at start of trial
uld not tell if groups were similar at start of trial
A
B
(A) Review authors’ judgments about each risk of bias item presented as percentages across all included studies 
(B) Review authors’ judgements about each risk of bias item for each included study 









A dve rse  even t 
10 .5  (1 , 24 )
11 .5  (1 , 22 )
17  (2 , 39 )
29  (18 , 36 )
10  (2 , 30 )
13  (8 , 21 )
4  (2 , 6 )
23  (23 , 25 )
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H e te rogene ity
29  (2 , 67 )
25  (2 ,62 )
36  (6 , 69 )
48  (1 , 75 )
34  (1 , 61 )
13  (0 , 27 )
9  (0 , 24)










Prevalence of adverse events following immunizaon (%)
aP
wP
Prevalence of adverse events following immunizaon    Mean (Min, Max )      eterogeneity
Prevalence of adverse events following immunizaon (%)
wP standalone
wP combinaon
Prevalence of adverse events following immunizaon   Mean (Min, Max )    Heterogeneity
B
Fig. 3. Mean prevalence and range of adverse events following first dose of whole cell and acellular vaccine (A) and following standalone DTwP and combination vaccines (B).
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not possible due to insufficient data.3.1.1.2. Adverse events associated with subsequent doses of whole-cell
pertussis. The first dose of wP vaccines was compared with second
and third doses of wP to assess whether the noted higher fre-
quency of AEFI with first wP dose changed with subsequent doses.
High heterogeneity did not allow for pooled AEFI prevalence esti-
mates to be reported at second or third dose of wP. Insufficient
data did not allow for a meta-analyses of injection site tenderness
and HHE following second dose of wP. An effect estimate was not
reported for seizure following second dose of wP as only one study
reported this AEFI (Monteiro, 2010). The prevalence of AEFI with
second dose of wP ranged from 0 to 71%, with irritability being
the most prevalent. The prevalence ranges for third dose of wP
spanned from 0 to 61%, with local reactions occurring most
frequently.3.1.2. Meta-analyses comparing adverse events associated with first
doses of wP and aP
Although twelve of the included studies were two-armed studies
that assessed AEFI by vaccine type, only eleven of the two-armed
studies were included in the meta-analyses as one (Deloria,
1995) did not contain data on AEFI at first dose of either vaccine
type. 14 864 participants were included in meta-analyses to calcu-
late risk ratios for AEFI at first dose of wP as compared to first dose
of aP.Fig. 4. Local reaction risk ratios followiLocal reaction risk ratios (general local reactions, injection site
swelling and injection site tenderness) are displayed in Fig. 4,
while systemic reaction risk ratios (fever over 38 C, drowsiness,
vomiting and anorexia) are displayed in Fig. 5. The pooled risk ratio
for irritability could not be reported due to high heterogeneity (I2
= 84.4%). Although heterogeneity for anorexia (I2 = 54.7%) was
slightly above the threshold, the risk ratio was retained as a forest
plot as it showed the pooled summary consistently with the visual
distribution of the data from individual studies. All calculated risk
ratios were >1 which showed an increased risk following first dose
of wP compared to first dose of aP [generalised local reactions RR
2.73 (2.33, 3.21), injection site tenderness RR 4.15 (3.24, 5.31),
injection site swelling RR 4.38 (2.70, 7.12), fever over 38 C RR
9.21 (5.39, 15.76), drowsiness RR 1.34 (1.18, 1.52) and vomiting
RR 1.28 (0.91, 1.79)]. Seizures were reported by three wP studies
with frequencies of 0.0004%, 0.03% and 11.3%, while HHE were
reported by three wP studies with frequencies of 0.0005%,
0.0006%, and 32.3%. Meta-analyses could not be performed for per-
sistent crying, seizure or HHE as no included studies reported on
these AEFI at first dose of aP.3.1.3. Sensitivity analysis
Studies assessed as having high risk of bias were planned to be
removed from meta-analyses in order to assess how bias may have
affected the review findings. No studies, however, were deemed to
have a high risk of bias, therefore, a sensitivity analysis was not
carried out.ng first dose of pertussis vaccines.
Fig. 5. Systemic reaction risk ratios following first dose of pertussis vaccines.
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In this review, we have systematically compared and quantified
the prevalence of AEFI at first doses of wP and aP vaccines. The
main findings of this review include: 1) primary vaccination with
either wP or aP vaccines was associated with a number of adverse
events at varying frequencies; 2) the first dose of wP was associ-
ated with higher frequencies of AEFI than the first dose of aP; 3)
the diversity and range of AEFI with second and third doses of
wP did not differ to that of first dose of wP; 4) most of the pub-
lished information on AEFI with wP and aP vaccines is from high
income countries. Taken together, our review results corroborate
the existing notion that primary doses [1–3] of wP vaccines are
more reactogenic than primary doses of aP vaccines. Based upon
the WHO’s AEFI causality assessment, we presume the AEFI
reported in this review to be resultant of the vaccine products
[66]. Although interesting, these results are not surprising as the
formulation of wP vaccines is crude and complex while purified
components of pertussis bacteria are contained in aP vaccines.
There is no known medical intervention that is considered to be
100% safe. Optimal safety (absence of serious adverse reactions),
however, is a universal prerequisite to any vaccine being used
[67]. Our results show first dose vaccination with both wP and
aP causes local and systemic adverse events. The most common
local reactions induced by both vaccine types was swelling at the
injection site. This type of local reaction, which is due to tissue
inflammation, is expected and common to adjuvanted vaccines
[68]. Local reactions are generally considered minor in clinical tri-
als [66]. Both local and systemic reactions were more commonlyreported following first dose of wP as compared to first dose of
aP. Persistent crying, however, was found to be more frequent fol-
lowing first dose of aP and these results may be due to lack of stan-
dardized AEFI case definitions. The frequencies of local and
systemic AEFI were not found to differ by the number of wP doses
administered. Two AEFI (drowsiness and vomiting) seemed to
occur more frequently when DTwP was given in combination for-
mulation with other antigens as compared to a standalone dose,
however there was insufficient data to make any conclusions
regarding this finding. The other vaccines included with DTwP in
the same formulation are generally considered to have good safety
profiles when used on their own, thus the apparent association
between formulation and some AEFI warrants further investiga-
tion. Except for vomiting, the most severe AEFI such as seizure
and HHE were reported with wP but not with aP. Even though
the occurrence of these severe AEFI following wP administration
were rare, such reactions are of concern to parents and may con-
tribute to vaccine hesitancy and loss of public confidence in vacci-
nes [69]. For example, Japan temporarily suspended vaccination
against B. pertussis after two infants died within 24 h of receiving
the wP vaccine in 1974 [70]. Sporadic reports of rare and severe
AEFI with wP were enough to warrant the switch to aP in many
high-income countries.
The switch from wP to aP has not yet taken place in many low and
middle-income countries (LMICs) [4]. Therefore, the pertussis vac-
cine safety profiles collated in this review contain data predomi-
nantly from high income countries in regard to aP. Due to
suboptimal surveillance systems in LMICs, it may be possible that
AEFI are being under-reported in these settings [71]. There is,
J. Patterson et al. / Vaccine 36 (2018) 6007–6016 6015however, effort to improve pharmacovigilance in LMICs as optimal
AEFI surveillance systems are crucial for strengthening immunisa-
tion programs [67].
The number and type of antigens contained in aP vaccines may be a
factor in AEFI, however due to insufficient data, this could not be
explored. Other limitations of this study include the lack of stan-
dardised criteria to assess and define AEFI across all studies, which
limited the quality of the data in this review. Thirdly, some AEFI
reports such as reports of extensive limb swelling associated with
aP may have been excluded due to the strict 72-hour observation
time limit applied in the inclusion criteria of review. The WHO
and Brighton Collaboration are dedicating recourses to standardis-
ing AEFI criteria for future studies. Our review, however, utilised a
strict AEFI definition and assessment criteria to mitigate this limi-
tation. Lastly, many studies were excluded from inclusion in this
review because adverse events were not reported by dose number,
a point we urge future studies to consider. Despite the exclusion of
many studies, the sample size of this review remained large.5. Conclusion
Our results confirm that the first dose of wP is more reactogenic
compared to aP and as such the proposed wP prime followed by
aP boost pertussis vaccination strategy should be approached with
caution. The WHO recommends a switch from wP to aP only where
countries are able to afford adding periodic booster doses and
maternal immunisation to the vaccination schedule. Our results
suggest that in addition to cost and efficacy, the safety profile of
wP vaccines could be a large factor limiting the continuation of
wP use in LMICs. Irrespective of reports suggesting greater efficacy
of wP compared to aP, the association of severe AEFI with wP may
compromise vaccine uptake in the long run. Vaccines with low
reactogenicity are crucial to ensuring high coverage in national
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